The recently emerged COVID-19 has been declared a pandemic by the World Health Organization as to date; no therapeutic drug/vaccine is available for the treatment. Due to the lack of time and the urgency to contain the pandemic, computational screening appears to be the best tool to find a therapeutic solution. Accumulated evidence suggests that many phyto-compounds possess anti-viral activity. Therefore, we identified possible phyto-compounds that could be developed and used for COVID-19 treatment. In particular, molecular docking was used to prioritize the possible active phytocompounds against two key targets namely RNA dependent RNA polymerase (RdRp) and main protease (M pro) of SARS-CoV-2. In this study, an antiviral drug-Remdesivir (RdRp inhibitor) and Darunavir (M pro inhibitor) are used as reference drugs. This study revealed that phyto-molecules-Mulberroside-A/C/E/F, Emblicanin A, Nimbolide, and Punigluconin showed high binding affinity against RdRp while Andrographolides, Mulberrosides, Anolignans, Chebulic acid, Mimusopic acid, and Punigluconin showed better binding affinity against M pro as compared with the reference drug. Furthermore, ADME profiles validated the drug-likeness properties of prioritized phyto-compounds. Besides, to assess the stability, MD simulations studies were performed along with reference inhibitors for M pro (Darunavir) and RdRp (Remdesivir). Binding free energy calculations (MM-PBSA) revealed the estimated value (DG) of M pro _Darunavir; M pro _Mulberroside E; RdRp_Remdesivir and RdRp_Emblicanin A were À111.62 ± 6.788, À141.443 ± 9.313, 30.782 ± 5.85 and À89.424 ± 3.130 kJmol À1 , respectively. Taken together, the study revealed the potential of these phyto-compounds as inhibitors of RdRp and M pro inhibitor that could be further validated against SARS-CoV-2 for clinical benefits.